- Details
- Christopher Wallis and Zachary Klaassen review the publication titled "Racial and Ethnic Disparities in the Use of Prostate Magnetic Resonance Imaging Following an Elevated Prostate-Specific Antigen Test." The study evaluated the association between race and ethnicity and the mean time between prostate-specific antigen (PSA) and magnetic resonance imaging (MRI). Among men with elevated PSA results...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss the article published in the Journal of Nuclear Medicine reporting on the first retrospective data on the detection efficacy and potential impact of 18F-rhPSMA-7.3 on clinical management in a homogeneous cohort of patients with biochemical recurrence after radical prostatectomy, and prior to any salvage therapy. 18F-rhPSMA-7.3 is under investigation...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss the JAMA Oncology article titled "Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone." The authors of this study aimed to investigate the differences in outcomes with first-line abiraterone therapy between African American and non-Hispanic White men with mCRPC in...
|
- Details
- Christopher Wallis and Zachary Klaassen highlight the Journal of Nuclear Medicine article titled "PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: an international multicenter study." The authors' findings support the new EAU classification for biochemically recurrent prostate cancer (BCR), that BCR high-risk groups have...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss the International, Randomized Phase III ANZUP ENZAMET trial published in the Journal of Clinical Oncology . In this trial, health-related quality of life (HRQL) was assessed with the European Organisation for Research and Treatment of Cancer core quality-of-life questionnaire and QLM-PR25 at weeks 0, 4, 12, and then every 12 weeks until progression....
|
- Details
- Christopher Wallis and Zachary Klaassen highlight the New England Journal of Medicine publication on the international, phase 3 ARASENS trial. The primary analysis involved 1306 patients (651 in the darolutamide group and 655 in the placebo group); 86.1% of the patients had disease that was metastatic at the time of the initial diagnosis. At the data cutoff date for the primary analysis (October 2...
|
- Details
- Zachary Klaassen and Christopher Wallis discuss a publication entitled, “Definitive Radiotherapy in lieu of Systemic Therapy for Oligometastatic Renal Cell Carcinoma: A single-arm, Single-center, Feasibility, Phase Two Trial”. In this study, the feasibility and efficacy of radiotherapy was tested to defer systemic therapy for patients with oligometastatic renal cell carcinoma. Dr. Wallis speaks to...
|
- Details
- Zachary Klaassen and Christopher Wallis discuss the ROBUUST collaboration publication entitled, “Risk Factors for Intravesical Recurrence After Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Cancer (Robuust Collaboration).” The objective of this study was to assess clinicopathologic risk factors for intravesical recurrence after radical nephroureterectomy for upper tract urotheli...
|
- Details
- In this UroToday Journal Club video, Drs Christopher Wallis and Zachary Klaassen highlight a JAMA Oncology publication "Association of Treatment Modality, Functional Outcomes, and Baseline Characteristics With Treatment-Related Regret Among Men With Localized Prostate Cancer". This work aimed to assess the association between treatment approach, functional outcomes, patient expectations, and treat...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss a publication entitled “Differential Activity of PARP Inhibitors in BRCA1-Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer.” Olaparib and Rucaparib are US Food and Drug Administration-approved for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA1/2 mutations. This data aimed to study the relativ...
|
